Clinical trial
The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.
NCT01931488 is registered in ClinicalTrials.gov with Tel-Aviv Sourasky Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2013
- Completion date
- January 31, 2016
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.